Complete Genomics (NASDAQ: [[ticker:GNOM]]), the Mountain View, CA-based company that sequences entire human genomes for researchers, has raised about $69 million in a new stock offering. The company sold 5.5 million shares at $12.50 apiece, a 6 percent discount to the closing market price the day before the deal was announced. The offering got a better reception than the company’s IPO from November—in which shares were sold for $9, and tumbled to $8.03 in the first day of trading. Complete Genomics ended the week at $14.33, with a market valuation of $372 million.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
